PROK
NASDAQ · Biotechnology
Prokidney Corp
$1.79
-0.04 (-2.19%)
Open$1.81
Previous Close$1.83
Day High$1.84
Day Low$1.76
52W High$3.48
52W Low$1.30
Volume—
Avg Volume1.29M
Market Cap565.34M
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+1,007.3% upside
Current
$1.79
$1.79
Target
$19.82
$19.82
$13.43
$19.82 avg
$25.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.03M | 45.98M | 42.93M |
| Net Income | -155,696,149 | 9.61M | 10.78M |
| Profit Margin | -7,725.2% | 20.9% | 25.1% |
| EBITDA | -357,587,195 | 17.18M | 13.92M |
| Free Cash Flow | — | 13.69M | 9.06M |
| Rev Growth | — | +20.4% | +3.7% |
| Debt/Equity | 0.00 | 0.62 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |